Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 9 Neoplasms 4 Neoplasm Metastasis 4 Multiple Myeloma 4 Gastrointestinal Stromal Tumors 4 Thyroid Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Kidney Neoplasms 2 Gastrointestinal Neoplasms 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Adenoma, Islet Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Meningioma 1

Interventions

Magnetic Resonance Spectroscopy 5 lutetium Lu 177 dotatate 4 Specimen Handling 4 Radiosurgery 3 gallium Ga 68 dotatate 2 Ga(III)-DOTATOC 2 Bevacizumab 2 regorafenib 1 pembrolizumab 1 olaparib 1 neratinib 1 capivasertib 1 cabozantinib 1 brigatinib 1 abemaciclib 1 X-Rays 1 Watchful Waiting 1 Tablets 1 Surveys and Questionnaires 1 Sunitinib 1 Radiotherapy, Intensity-Modulated 1 Protons 1 Proton Therapy 1 Photons 1 Observation 1 ONC206 1 Nivolumab 1 Mental Status and Dementia Tests 1 Lysine 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × Sunitinib × 90 days × Clear all

NCT06955169 2026-05-22

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Suspended

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡